Compare AMGN & XOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMGN | XOM |
|---|---|---|
| Founded | 1980 | 1870 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Integrated oil Companies |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.7B | 518.3B |
| IPO Year | N/A | N/A |
| Metric | AMGN | XOM |
|---|---|---|
| Price | $322.70 | $126.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $321.69 | $130.57 |
| AVG Volume (30 Days) | 2.8M | ★ 16.6M |
| Earning Date | 02-03-2026 | 01-30-2026 |
| Dividend Yield | 3.10% | ★ 3.32% |
| EPS Growth | ★ 65.12 | N/A |
| EPS | ★ 12.93 | 6.89 |
| Revenue | $35,971,000,000.00 | ★ $326,245,000,000.00 |
| Revenue This Year | $10.85 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | $25.17 | ★ $18.01 |
| Revenue Growth | ★ 10.56 | N/A |
| 52 Week Low | $261.28 | $97.80 |
| 52 Week High | $346.38 | $125.93 |
| Indicator | AMGN | XOM |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 63.19 |
| Support Level | $318.21 | $122.56 |
| Resistance Level | $343.05 | $124.86 |
| Average True Range (ATR) | 6.70 | 2.31 |
| MACD | -0.74 | 0.47 |
| Stochastic Oscillator | 20.61 | 88.95 |
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2024, it produced 3.0 million barrels of liquids and 8.1 billion cubic feet of natural gas per day. At the end of 2024, reserves were 19.9 billion barrels of oil equivalent, 69% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.3 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.